Study protocol of a phase II clinical trial (KSCC1501A) examining oxaliplatin + S-1 for treatment of HER2-negative advanced/ recurrent gastric cancer previously untreated with chemotherapy

ELEVATE – evaluating Temozolomide and Nivolumab in patients with advanced unresectable previously treated oesophagogastric adenocarcinoma with MGMT methylation: Study protocol for a single arm phase II trial

13 p | 5 | 3

Daily irradiation versus irradiation at two- to three-day intervals in stereotactic radiotherapy for patients with 1-5 brain metastases: Study protocol for a multicenter open-label randomized phase II trial

8 p | 3 | 2

Study protocol of a phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized rectal cancer

8 p | 3 | 2

Protocol for the 2ND-STEP study, Japan Clinical Oncology Group study JCOG1802: A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib

8 p | 2 | 1

PRognostic factor of Early Death In phase II Trials or the end of ‘sufficient life expectancy’ as an inclusion criterion? (PREDIT model)

8 p | 8 | 1

Laparoscopic versus open gastrectomy for elderly local advanced gastric cancer patients: Study protocol of a phase II randomized controlled trial

8 p | 15 | 1

Assessment of precision irradiation in early non-small cell lung cancer and interstitial lung disease (ASPIRE-ILD): Study protocol for a phase II trial

17 p | 11 | 1

Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): Study protocol of a phase I/II clinical trial

13 p | 9 | 0

The WIRE study a phase II, multi-arm, multicentre, non-randomised window-ofopportunity clinical trial platform using a Bayesian adaptive design for proof-ofmechanism of novel treatment strategies in operable renal cell cancer – a study protocol

11 p | 9 | 0